|
US4275149A
(en)
|
1978-11-24 |
1981-06-23 |
Syva Company |
Macromolecular environment control in specific receptor assays
|
|
US4318980A
(en)
|
1978-04-10 |
1982-03-09 |
Miles Laboratories, Inc. |
Heterogenous specific binding assay employing a cycling reactant as label
|
|
US4424200A
(en)
|
1979-05-14 |
1984-01-03 |
Nuc Med Inc. |
Method for radiolabeling proteins with technetium-99m
|
|
US4479930A
(en)
|
1982-07-26 |
1984-10-30 |
Trustees Of The University Of Massachusetts |
Amines coupled wth dicyclic dianhydrides capable of being radiolabeled product
|
|
GB8308235D0
(en)
|
1983-03-25 |
1983-05-05 |
Celltech Ltd |
Polypeptides
|
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
|
JPS61134325A
(ja)
|
1984-12-04 |
1986-06-21 |
Teijin Ltd |
ハイブリツド抗体遺伝子の発現方法
|
|
GB8607679D0
(en)
|
1986-03-27 |
1986-04-30 |
Winter G P |
Recombinant dna product
|
|
US4987071A
(en)
|
1986-12-03 |
1991-01-22 |
University Patents, Inc. |
RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
|
|
US5185243A
(en)
|
1988-08-25 |
1993-02-09 |
Syntex (U.S.A.) Inc. |
Method for detection of specific nucleic acid sequences
|
|
GB8928874D0
(en)
|
1989-12-21 |
1990-02-28 |
Celltech Ltd |
Humanised antibodies
|
|
GB9015198D0
(en)
|
1990-07-10 |
1990-08-29 |
Brien Caroline J O |
Binding substance
|
|
JPH07501451A
(ja)
|
1991-11-25 |
1995-02-16 |
エンゾン・インコーポレイテッド |
多価抗原結合タンパク質
|
|
DK0672142T3
(da)
|
1992-12-04 |
2001-06-18 |
Medical Res Council |
Multivalente og multispecifikke bindingsproteiner samt fremstilling og anvendelse af disse
|
|
US6121022A
(en)
|
1995-04-14 |
2000-09-19 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
|
GB9509957D0
(en)
|
1995-05-17 |
1995-07-12 |
Khalil Nasreen |
Post-translational activation of tgf-1 involving the tsp-1 receptor cd36
|
|
US5814468A
(en)
|
1996-03-27 |
1998-09-29 |
Coulter International Corp. |
Methods of enumerating receptor molecules for specific binding partners on formed bodies and in solution
|
|
US5958671A
(en)
|
1996-04-23 |
1999-09-28 |
Presidents And Fellows Of Harvard College |
Methods and compositions for regulating T cell subsets by modulating transcription factor activity
|
|
EP2003203A1
(en)
|
1996-12-23 |
2008-12-17 |
Immunex Corporation |
Ligand for receptor activator of nf-kappa b, ligand is member of TNF superfamily
|
|
US6316408B1
(en)
|
1997-04-16 |
2001-11-13 |
Amgen Inc. |
Methods of use for osetoprotegerin binding protein receptors
|
|
US6274338B1
(en)
*
|
1998-02-24 |
2001-08-14 |
President And Fellows Of Harvard College |
Human c-Maf compositions and methods of use thereof
|
|
DK1137941T4
(da)
|
1998-12-10 |
2014-01-06 |
Brystol Myers Squibb Company |
Protein-scaffolds til antistof-mimetika og andre bindingsproteiner
|
|
EP1161415B1
(en)
|
1999-03-15 |
2005-07-13 |
Axys Pharmaceuticals, Inc. |
N-cyanomethylamides as protease inhibitors
|
|
US6525036B2
(en)
|
2000-01-06 |
2003-02-25 |
Merck & Co., Inc. |
Compounds and compositions as protease inhibitors
|
|
ATE353974T1
(de)
|
2000-04-03 |
2007-03-15 |
Corixa Corp |
Verfahren, zusammensetzungen und kits zur identifizierung und überwachung von brustkrebs
|
|
US7700359B2
(en)
|
2000-06-02 |
2010-04-20 |
Novartis Vaccines And Diagnostics, Inc. |
Gene products differentially expressed in cancerous cells
|
|
MY143582A
(en)
|
2001-06-26 |
2011-05-31 |
Amgent Fremont Inc |
Antibodies to opgl
|
|
IL166244A0
(en)
|
2001-07-12 |
2006-01-15 |
Jefferson Foote |
Super humanized antibodies
|
|
GB0121033D0
(en)
|
2001-08-30 |
2001-10-24 |
Novartis Ag |
Organic compounds
|
|
AR036375A1
(es)
|
2001-08-30 |
2004-09-01 |
Novartis Ag |
Compuestos pirrolo [2,3-d] pirimidina -2- carbonitrilo, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos compuestos para la preparacion de medicamentos
|
|
JP4238138B2
(ja)
|
2001-12-22 |
2009-03-11 |
４−アンチボディ アーゲー |
遺伝的に修飾された脊椎動物前駆体リンパ球の生成方法及び異種結合タンパク質の産生を目的としたその使用。
|
|
SE0201980D0
(sv)
|
2002-06-24 |
2002-06-24 |
Astrazeneca Ab |
Novel compounds
|
|
AU2003286499A1
(en)
|
2003-10-17 |
2004-06-06 |
The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Interference with c-maf function in multiple myeloma
|
|
WO2005060722A2
(en)
|
2003-12-18 |
2005-07-07 |
President And Fellows Of Hardvard College |
Modulation of immune system function by modulation of polypeptide arginine methyltransferases
|
|
WO2007053245A2
(en)
|
2005-09-20 |
2007-05-10 |
Immunivest Corporation |
Methods and composition to generate unique sequence dna probes, iabeling of dna probes and the use of these probes
|
|
US9134237B2
(en)
|
2005-09-20 |
2015-09-15 |
Janssen Diagnotics, LLC |
High sensitivity multiparameter method for rare event analysis in a biological sample
|
|
EP1777523A1
(en)
|
2005-10-19 |
2007-04-25 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method
|
|
EP2046971B1
(en)
|
2006-06-30 |
2012-04-04 |
University Of Southern California |
Quantifiable internal reference standards for immunohistochemistry and uses thereof
|
|
WO2008086800A2
(en)
|
2007-01-15 |
2008-07-24 |
Aarhus Universitet |
Predisposition to, prognosis for and treatment of breast cancer relating to human chromosome 16
|
|
WO2008098351A1
(en)
|
2007-02-14 |
2008-08-21 |
University Health Network |
Treatment of d-cyclin mediated proliferative diseases and hemotological malignancies
|
|
JP2010519219A
(ja)
|
2007-02-16 |
2010-06-03 |
パシフィック アロー リミテッド |
接着タンパク質に影響を及ぼすことによる癌細胞の移動または転移の遮断およびその新規化合物の使用
|
|
AU2008252853B2
(en)
|
2007-05-24 |
2011-12-01 |
Ablynx N.V. |
Amino acid sequences directed against RANK-L and polypeptides comprising the same for the treatment of bone diseases and disorders
|
|
RU2011101378A
(ru)
|
2008-06-16 |
2012-07-27 |
Сайвидон Дайагностикс Гмбх (De) |
Алгоритмы предсказания исхода у пациентов с узловой формой рака молочной железы после химиотерапии
|
|
WO2010110346A1
(ja)
|
2009-03-24 |
2010-09-30 |
独立行政法人理化学研究所 |
白血病幹細胞マーカー
|
|
WO2011039734A2
(en)
|
2009-10-02 |
2011-04-07 |
Enzo Medico |
Use of genes involved in anchorage independence for the optimization of diagnosis and treatment of human cancer
|
|
DK3091085T3
(da)
|
2010-10-06 |
2019-05-06 |
Inst Catalana Recerca Estudis Avancats |
Fremgangsmåde til at designe en terapi mod brystcancermetastase
|
|
US20140162887A1
(en)
|
2011-02-04 |
2014-06-12 |
Bioarray Therapeutics, Inc. |
Methods of using gene expression signatures to select a method of treatment, predict prognosis, survival, and/or predict response to treatment
|
|
EP2650682A1
(en)
*
|
2012-04-09 |
2013-10-16 |
Fundació Privada Institut de Recerca Biomèdica |
Method for the prognosis and treatment of cancer metastasis
|
|
EP3467124A1
(en)
*
|
2012-06-06 |
2019-04-10 |
Fundació Institut de Recerca Biomèdica IRB (Barcelona) |
Method for the diagnosis, prognosis and treatment of lung cancer metastasis
|
|
US10119171B2
(en)
|
2012-10-12 |
2018-11-06 |
Inbiomotion S.L. |
Method for the diagnosis, prognosis and treatment of prostate cancer metastasis
|
|
JP6074049B2
(ja)
*
|
2012-10-12 |
2017-02-01 |
インバイオモーション エセ．エレ． |
ｃ−ＭＡＦを用いた前立腺がん転移の診断、予後診断および処置のための方法
|
|
AU2014229505B2
(en)
|
2013-03-15 |
2020-02-27 |
Fundacio Institut De Recerca Biomedica (Irb Barcelona) |
Method for the prognosis and treatment of cancer metastasis
|
|
US20160040247A1
(en)
|
2013-03-15 |
2016-02-11 |
Fundació Institut De Recerca Biomèdica (Irb Barcelona) |
Method for the diagnosis, prognosis, and tratment of cancer metastasis
|
|
US20160032399A1
(en)
|
2013-03-15 |
2016-02-04 |
Inbiomotion S.L. |
Method for the Prognosis and Treatment of Renal Cell Carcinoma Metastasis
|
|
JP6550045B2
(ja)
|
2013-10-09 |
2019-07-24 |
フンダシオ、インスティトゥト、デ、レセルカ、ビオメディカ（イエレベ、バルセロナ）Ｆｕｎｄａｃｉｏ Ｉｎｓｔｉｔｕｔ Ｄｅ Ｒｅｃｅｒｃａ Ｂｉｏｍｅｄｉｃａ （Ｉｒｂ Ｂａｒｃｅｌｏｎａ） |
乳がんに由来する骨の転移がんの予後診断および処置のための方法
|
|
KR20170093182A
(ko)
|
2014-12-11 |
2017-08-14 |
인바이오모션 에스.엘. |
인간 c-maf에 대한 결합 구성원
|
|
PT3458610T
(pt)
|
2016-05-25 |
2021-06-29 |
Inbiomotion Sl |
Tratamento terapêutico de cancro da mama baseado no estado de c-maf
|
|
WO2019102380A1
(en)
|
2017-11-22 |
2019-05-31 |
Inbiomotion S.L. |
Therapeutic treatment of breast cancer based on c-maf
|